Clinical Research Also Showcases Innovative Approaches to Expanding TomoTherapy Platform Functionality SUNNYVALE, Calif. , Aug. 4, 2016 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new studies demonstrating the TomoTherapy® System's leading-edge adaptive therapy
Data Also Underscores Potential Benefits of CyberKnife System Sub-millimeter Accuracy in Preserving Quality of Life after Treatment for Prostate Cancer MADISON, Wis. , March 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that new data presented at the 2024 Radiosurgery
More Than 70 Abstracts Build on the Clinical Evidence Supporting the Use of These Technologies SUNNYVALE, Calif. , May 10, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that clinical studies continue to validate the versatility of the company's CyberKnife® and
Studies Show the System Provides Excellent Outcomes Throughout the Cancer Treatment Journey, from Primary Cases to Recurrence and Metastatic Disease SUNNYVALE, Calif. , May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies on the clinical use of the
Multiple Studies Presented at ESTRO 36 Demonstrate System Improves Tumor Control withReduced Toxicities SUNNYVALE, Calif. , May 11, 2017 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that studies continue to demonstrate the unmatched flexibility of the cutting-edge
Clinical Research on the CyberKnife® System, Including the Multileaf Collimator, Presented at Leading Scientific Meeting for Medical Physicists SUNNYVALE, Calif., August 4, 2016 – Accuray Incorporated (NASDAQ: ARAY) announced today that more than 45 studies on the use of the CyberKnife®
Prospective, Multicenter Study Supported by the French National Institute of Cancer Also Demonstrates that Treatment with the TomoTherapy Platform Resulted in a Significantly Better Cancer-Specific Survival Rate and Post-Treatment Salivary Function SUNNYVALE, Calif.
Updated ASTRO Model Policy Endorses Stereotactic Body Radiation Therapy (SBRT) for Prostate Cancer SUNNYVALE, Calif. , May 21, 2013 /PRNewswire/ -- Accuray Incorporated (Nasdaq: ARAY), announced today the publication of study results involving hundreds of prostate cancer patients treated with the
SUNNYVALE, Calif. , Oct. 26, 2022 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the Japanese Ministry of Health, Labor and Welfare (MHLW) has approved reimbursement for the CyberKnife ® System for the treatment of trigeminal neuralgia (TN).
SUNNYVALE, Calif. , May 30, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that recently published data from two new studies demonstrate the benefits of the TomoTherapy ® System in the delivery of total body irradiation (TBI), a procedure commonly used to prepare patients
*The quarterly and year-end results reported herein were subsequently revised for adjustments that were immaterial, individually and in the aggregate. The revised quarterly and year-end results are included in our Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the "SEC") on August 25, 2020, and are accessible on our website at https://investors.accuray.com/financial-information/sec-filings and on the SEC's website at www.sec.gov.